The fibrin-derived peptide Bβ15-42 is cardioprotective in a pig model of myocardial ischemia-reperfusion injury

Critical Care Medicine

Volumn 35, Issue 7, 2007, Pages 1730-1735

  Roesner, Jan P ^a   Petzelbauer, Peter ^b   Koch, Alexander ^c   Mersmann, Jan ^d   Zacharowski, Paula A ^c   Boehm, Olaf ^d   Reingruber, Sonja ^e   Pasteiner, Waltraud ^e   Mascher, Daniel ^f   Wolzt, Michael ^b   Barthuber, Carmen ^d   Nöldge Schomburg, Gabi E F ^a   Scheeren, Thomas W L ^a   Zacharowski, Kai ^c,d  

^a ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c BRISTOL ROYAL INFIRMARY   (United Kingdom)

^d UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^e Fibrex Medical Inc   (Austria)

^f Pharm Analyt Laboratory GmbH   (Austria)

Author keywords

Fibrin fragments; Human; Ischemia; Pig; Reperfusion

Indexed keywords

FIBRIN DERIVATIVE; INTERLEUKIN 6; PEPTIDE; PEPTIDE BBETA[15-42]; PLACEBO; TROPONIN I; UNCLASSIFIED DRUG; CARDIOTONIC AGENT; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN BBETA (15 42); FIBRINOGEN BBETA (15-42); PEPTIDE FRAGMENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HEART INFARCTION SIZE; HEART INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEMODYNAMICS; HUMAN; ISCHEMIC PRECONDITIONING; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RAT STRAIN; RECOMMENDED DRUG DOSE; REPERFUSION INJURY; STATISTICAL SIGNIFICANCE; SWINE; UNIVERSITY HOSPITAL; UNSPECIFIED SIDE EFFECT; ADOLESCENT; ANALYSIS OF VARIANCE; ANIMAL; COMPARATIVE STUDY; DOG; DRUG TOXICITY; HALF LIFE TIME; MIDDLE AGED; PATHOLOGY; PHASE 1 CLINICAL TRIAL; RAT; TISSUE DISTRIBUTION;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANIMALS; CARDIOTONIC AGENTS; DOGS; DOUBLE-BLIND METHOD; DRUG TOXICITY; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; RATS; REPERFUSION INJURY; SWINE; TISSUE DISTRIBUTION;

EID: 34250858254     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000269035.30231.76     Document Type: Article

References (23)

1. Miller TD, Hodge DO, Sutton JM, et al: Usefulness of technetium-99m sestamibi infarct size in predicting posthospital mortality following acute myocardial infarction. Am J Cardiol 1998; 81:1491-1493
2. Frangogiannis NG, Smith CW, Entman ML: The inflammatory response in myocardial infarction. Cardiovasc Res 2002; 53:31-47
3. Xu Z, Mueller RA, Park SS, et al: Cardioprotection with adenosine A2 receptor activation at reperfusion. J Cardiovasc Pharmacol 2005; 46:794-802
4. Jones SP, Bolli R: The ubiquitous role of nitric oxide in cardioprotection. J Mol Cell Cardiol 2006; 40:16-23
5. Prasad A, Gersh BJ: Management of microvascular dysfunction and reperfusion injury. Heart 2005; 91:1530-1532
6. Cannon RO III: Mechanisms, management and future directions for reperfusion injury after acute myocardial infarction. Nat Clin Pract Cardiovasc Med 2005; 2:88-94
7. Bolli R, Becker L, Gross G, et al: Myocardial protection at a crossroads: The need for translation into clinical therapy. Circ Res 2004; 95:125-134
8. Maxwell MP, Hearse DJ, Yellon DM: Species variation in the coronary collateral circulation during regional myocardial ischaemia: A critical determinant of the rate of evolution and extent of myocardial infarction. Cardiovasc Res 1987; 21:737-746
9. del Rio CL, McConnell PI, Clymer BD, et al: Early time course of myocardial electrical impedance during acute coronary artery occlusion in pigs, dogs, and humans. J Appl Physiol 2005; 99:1576-1581
10. Petzelbauer P, Zacharowski PA, Miyazaki Y, et al: The fibrin-derived peptide B beta(15-42) protects the myocardium against ischemia-reperfusion injury. Nat Med 2005; 11:298-304
11. Zacharowski K, Zacharowski P, Friedl P, et al: The effects of the fibrin-derived peptide Bb15-42 in acute and chronic models of myocardial ischemia-reperfusion. Shock 2007; 27:631-637
12. Cinca J, Warren M, Carreno A, et al: Changes in myocardial electrical impedance induced by coronary artery occlusion in pigs with and without preconditioning: Correlation with local ST-segment potential and ventricular arrhythmias. Circulation 1997; 96:3079-3086
13. Schulz R, Rose J, Heusch G. Involvement of activation of ATP-dependent potassium channels in ischemic preconditioning in swine. Am J Physiol 1994; 267:H1341-H1352
14. Horstick G, Berg O, Heimann A, et al: Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: Dose-related beneficial versus detrimental effects. Circulation 2001; 104:3125-3131
15. Zacharowski K, Olbrich A, Otto M, et al: Effects of the prostanoid EP3-receptor agonists M&B 28767 and GR 63799X on infarct size caused by regional myocardial ischaemia in the anaesthetized rat. Br J Pharmacol 1999; 126:849-858
16. Bennermo M, Held C, Green F, et al: Prognostic value of plasma interleukin-6 concentrations and the -174 G > C and -572 G > C promoter polymorphisms of the interleukin-6 gene in patients with acute myocardial infarction treated with thrombolysis. Atherosclerosis 2004; 174:157-163
17. Ikonomidis I, Athanassopoulos G, Lekakis J, et al: Myocardial ischemia induces interleukin-6 and tissue factor production in patients with coronary artery disease: A dobutamine stress echocardiography study. Circulation 2005; 112:3272-3279
18. Matsushita K, Iwanaga S, Oda T, et al: Interleukin-6/soluble interleukin-6 receptor complex reduces infarct size via inhibiting myocardial apoptosis. Lab Invest 2005; 85:1210-1223
19. Gorlatov S, Medved L: Interaction of fibrin (ogen) with the endothelial cell receptor VEcadherin: Mapping of the receptor-binding site in the NH2-terminal portions of the fibrin beta chains. Biochemistry 2002; 41:4107-4116
20. Bach TL, Barsigian C, Yaen CH, et al: Endothelial cell VE-cadherin functions as a receptor for the beta15-42 sequence of fibrin. J Biol Chem 1998; 273:30719-30728
21. Levi M, Choi G, Schoots I, et al: Beyond sepsis: Activated protein C and ischemia-reperfusion injury. Crit Care Med 2004; 32(Suppl):S309-S312
22. McCallion K, Harkin D, Gardiner KR: Role of adenosine in immunomodulation: Review of the literature. Crit Care Med 2004; 32:273-277
23. Roy S, Khanna S, Kuhn DE, et al: Transcriptome analysis of the ischemia-reperfused remodeling myocardium: Temporal changes in inflammation and extracellular matrix. Physiol Genomics 2006; 25:364-374